Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Prostascint Helps Pinpoint Recurrence Of Prostate Cancer After Prostatectomy NEW ORLEANS, April 14, 1997 -- A new imaging agent called Prostascint(TM) may be a useful tool in helping physicians determine whether prostate cancer has spread elsewhere in the body following a prostatectomy, thus enabling more effective treatment. That finding was reported today by Cleveland Clinic physicians at the American Urological Association annual meeting. The Cleveland Clinic studied 38 patients who had undergone radical prostatectomies. Following surgery, each patient experienced an increase in prostate specific antigen (PSA), which often is indicative of the cancer having spread elsewhere in the body. "The problem we face in these situations is determining whether the cancer is locally recurrent in the tissue surrounding the prostate or it has spread to another area of the body. The PSA test won't tell us that," said Eric A. Klein, M.D., head of The Cleveland Clinic's Section of Urologic Oncology. "Knowing the location and extent of the cancer is essential in determining the most effective treatment." In the study, physicians infused the patients with Prostascint, an antibody that has been tagged with a radioactive tracer. Between two and five days later, the patients were scanned with a gamma camera. The antibody attaches itself to prostate tumors, and the radioactive tracer allows physicians to pinpoint the location of those tumors through the scans. In the study, scans of 21 of the 38 patients indicated a recurrence, with six being local tumors, 11 distant metastases, and four both local and distant disease. None of the recurrences were identified by more commonly used scanning techniques such as CT or MRI, while two were identified by bone scans. "About 30 percent of patients who undergo prostatectomies will experience a recurrence of the disease, so the need for effective diagnostic tools is significant," said Dr. Klein. "If we can positively determine the existence of a recurrence and pinpoint its location in a timely manner, we can potentially save a lot of lives." The study was funded by the Cytogen Corporation, which is marketing Prostascint. E-mail this page to a friend or colleague! To print, use this version